Search

ObjectivesThe growing rate of retraction of scientific publications has attracted much attention within the academic community, but there is little knowledge about the nature of such retractions in schizophrenia-related research. This study aimed to analyze the characteristics of retractions of schizophrenia-related publications.Materials and methodsThe Web of Science was searched for eligible studies. A bibliometric analysis was conducted to describe the characteristics of the retractions using R software and Excel 2019. Content analysis was conducted to examine the essential components of retraction notices.ResultsA total of 36 retracted publications with 415 citations were identified from 1997 to 2021, of which, 83.3% occurred in the last decade. The overall retraction rate was 0.19%, with most of them (29; 80.56%) from the United Kingdom. The retractions were published in 33 journals, and the 2020 IFs ranged between 0.17 and 49.96 (Median = 3.93). The retractions involved 21 research areas, particularly in Psychiatry (19; 52.78%), Neurosciences and Neurology (10; 27.78%), and Psychology (7; 19.44%). Data issues (17; 42.22%), administrative errors of the publishers (5; 13.89%), and study design (4; 11.11%) were the top three reasons for retractions.ConclusionThis study provides an insight into retractions of schizophrenia-related publications. Institutional governance should be further strengthened to improve the scrutiny of publications, prevent continuing citations, and erroneous propagation after retraction.

Supplemental Material, sj-pdf-1-jgp-10.1177_08919887221078559 for Network Analysis of Depression, Anxiety, Posttraumatic Stress Symptoms, Insomnia, Pain, and Fatigue in Clinically Stable Older Patients With Psychiatric Disorders During the COVID-19 Outbreak by Wen Li, MD, PhD, Na Zhao, PhD, Xiaona Yan, MSc, Xiuying Xu, PhD, Siyun Zou, MD, Huan Wang, MD, Yulong Li, MD, Xiangdong Du, MD, Lan Zhang, MD, Qinge Zhang, MD, Teris Cheung, PhD, Gabor S. Ungvari, MD, PhD, Chee H. Ng, MBBS, MD, and Yu-Tao Xiang, MD, PhD in Journal of Geriatric Psychiatry and Neurology

Supplemental Material, sj-docx-1-cpa-10.1177_0706743720979917 for Plant-based Medicines (Phytoceuticals) in the Treatment of Psychiatric Disorders: A Meta-review of Meta-analyses of Randomized Controlled Trials: Les médicaments à base de plantes (phytoceutiques) dans le traitement des troubles psychiatriques: une méta-revue des méta-analyses d’essais randomisés contrôlés by Jerome Sarris, Wolfgang Marx, Melanie M. Ashton, Chee H. Ng, Nicole Galvao-Coelho, Zahra Ayati, Zhang-Jin Zhang, Siegfried Kasper, Arun Ravindran, Brian H. Harvey, Adrian Lopresti, David Mischoulon, Jay Amsterdam, Lakshmi N. Yatham and Michael Berk in The Canadian Journal of Psychiatry

Supplemental Material, MITO-NAC_Physical_activity_Supplementary_Material for Physical Activity as a Predictor of Clinical Trial Outcomes in Bipolar Depression: A Subanalysis of a Mitochondrial-Enhancing Nutraceutical Randomized Controlled Trial by Melanie M. Ashton, Mohammadreza Mohebbi, Alyna Turner, Wolfgang Marx, Michael Berk, Gin S. Malhi, Chee H. Ng, Sue M. Cotton, Seetal Dodd, Jerome Sarris, Malcolm Hopwood, Brendon Stubbs and Olivia M. Dean in The Canadian Journal of Psychiatry

Supplemental_Figure_1 for Prevalence of Workplace Violence Against Health-Care Professionals in China: A Comprehensive Meta-Analysis of Observational Surveys by Li Lu, Min Dong, Shi-Bin Wang, Ling Zhang, Chee H. Ng, Gabor S. Ungvari, Jun Li, and Yu-Tao Xiang in Trauma, Violence, & Abuse

Supplemental material, Table_S2 for Minocycline as adjunctive treatment for major depressive disorder: Pooled data from two randomized controlled trials by Robson Zazula, Muhammad Ishrat Husain, Mohammadreza Mohebbi, Adam J Walker, Imran B Chaudhry, Ameer B Khoso, Melanie M Ashton, Bruno Agustini, Nusrat Husain, JFW Deakin, Allan H Young, Michael Berk, Buranee Kanchanatawan, Chee H Ng, Michael Maes, Lesley Berk, Ajeet B Singh, Gin S Malhi and Olivia M Dean in Australian & New Zealand Journal of Psychiatry

Supplemental material, Table_S1 for Minocycline as adjunctive treatment for major depressive disorder: Pooled data from two randomized controlled trials by Robson Zazula, Muhammad Ishrat Husain, Mohammadreza Mohebbi, Adam J Walker, Imran B Chaudhry, Ameer B Khoso, Melanie M Ashton, Bruno Agustini, Nusrat Husain, JFW Deakin, Allan H Young, Michael Berk, Buranee Kanchanatawan, Chee H Ng, Michael Maes, Lesley Berk, Ajeet B Singh, Gin S Malhi and Olivia M Dean in Australian & New Zealand Journal of Psychiatry

Supplementary_File_1_-_list_of_BD_agents_from_search for A Systematic Review of Nutraceuticals for the Treatment of Bipolar Disorder: Une revue systématique des nutraceutiques pour le traitement du trouble bipolaire by Melanie M. Ashton, Bianca E. Kavanagh, Wolfgang Marx, Michael Berk, Jerome Sarris, Chee H. Ng, Malcolm Hopwood, Lana J. Williams and Olivia M. Dean in The Canadian Journal of Psychiatry

Supplemental material, Supplementary_file_2-4 for Diet quality, dietary inflammatory index and body mass index as predictors of response to adjunctive N-acetylcysteine and mitochondrial agents in adults with bipolar disorder: A sub-study of a randomised placebo-controlled trial by Melanie M Ashton, Olivia M Dean, Wolfgang Marx, Mohammadreza Mohebbi, Michael Berk, Gin S Malhi, Chee H Ng, Sue M Cotton, Seetal Dodd, Jerome Sarris, Malcolm Hopwood, Keshav Faye-Chauhan, Yesul Kim, Sarah R Dash, Felice N Jacka, Nitin Shivappa, James R Hebert and Alyna Turner in Australian & New Zealand Journal of Psychiatry

Supplemental Material, 19037-e-CJP-2019-134-OR.R1-__Abstract_for_translation-134 for Physical Activity as a Predictor of Clinical Trial Outcomes in Bipolar Depression: A Subanalysis of a Mitochondrial-Enhancing Nutraceutical Randomized Controlled Trial by Melanie M. Ashton, Mohammadreza Mohebbi, Alyna Turner, Wolfgang Marx, Michael Berk, Gin S. Malhi, Chee H. Ng, Sue M. Cotton, Seetal Dodd, Jerome Sarris, Malcolm Hopwood, Brendon Stubbs and Olivia M. Dean in The Canadian Journal of Psychiatry

Supplemental material, Supplementary_file_1 for Diet quality, dietary inflammatory index and body mass index as predictors of response to adjunctive N-acetylcysteine and mitochondrial agents in adults with bipolar disorder: A sub-study of a randomised placebo-controlled trial by Melanie M Ashton, Olivia M Dean, Wolfgang Marx, Mohammadreza Mohebbi, Michael Berk, Gin S Malhi, Chee H Ng, Sue M Cotton, Seetal Dodd, Jerome Sarris, Malcolm Hopwood, Keshav Faye-Chauhan, Yesul Kim, Sarah R Dash, Felice N Jacka, Nitin Shivappa, James R Hebert and Alyna Turner in Australian & New Zealand Journal of Psychiatry

Supplemental material, Supplemental_Files__Apr_29,_2019 for Adjunctive minocycline for major mental disorders: A systematic review by Wei Zheng, Xiao-Min Zhu, Qing-E Zhang, Gen Cheng, Dong-Bin Cai, Jie He, Chee H Ng, Gabor S Ungvari, Xiao-Jiang Peng, Yu-Ping Ning and Yu-Tao Xiang in Journal of Psychopharmacology

Background Metabolic syndrome in patients with schizophrenia is a major health concern. The efficacy and safety of adjunctive rosuvastatin in treating dyslipidemia were controversial. Aims To assess the efficacy and safety of adjunctive rosuvastatin for dyslipidemia in patients with schizophrenia. Methods We systematically searched for relevant controlled clinical trials from the following databases: PubMed, PsycINFO, Cochrane Library, China Knowledge Network, WanFang Database and Chinese Biomedical Database up to September 28, 2017. Standardized mean difference (SMD) and risk ratio (RR) along with their 95% confidence intervals (CIs) were calculated. The quality of the included studies was assessed using the Cochrane risk of bias assessment tool. The GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) system recommendation grading method was used as the reference standard. Results Four studies (n=274) comparing rosuvastatin (n=138) and control (n=136) groups were identified and analyzed. Adjunctive rosuvastatin showed greater efficacy than control group in low density lipoprotein cholesterol (LDL-C) [4 trials, n=272, SMD: -1.31 (95%CI: -1.93, -0.70), I2=81%], total cholesterol (2 trials, n=164, SMD: -2.00 (95%CI: -2.79, -1.21); I2=76%) and triglycerides (2 trials, n=164, SMD: -1.05 (95%CI: -1.38, -0.72); I2=0%), but not in high density lipoprotein cholesterol (2 trials, n=164, SMD: 0.14 (95%CI: -0.16, 0.45); I2=0%). After removing one study without randomization for LDL-C, significance remained [3 trials, n=172, SMD:-1.07 (95%CI: -1.60, -0.53); I2=63%]. No significant group differences regarding body weight (3 trials, n=208, SMD: -0.40 (95%CI:-1.29, 0.49); I2=89%), body mass index (2 trials, n=164, SMD: -0.34 (95%CI: -1.23, 0.56); I2=87%), waist circumference (3 trials, n=208, SMD): -0.43 (95%CI: -1.31, 0.46); I2=89%), and fasting glucose (4 trials, n=272, SMD: -0.25 (95%CI: -0.65, 0.15); I2=62%) were observed. The adverse reactions and any cause discontinuation rate were similar between the groups. According to the GRADE approach, the evidence levels of main outcomes were rated as “very low” (35.3%) to “low” (64.7%). Of them, the primary outcome (LDL-C) was rated as “very low “. Conclusions The data available on the effectiveness and safety of adjunctive rosuvastatin in treating dyslipidemia for patients with schizophrenia is insufficient to come to a definitive interpretation about its efficacy and safety. Further high quality RCTs with extended treatment duration are warranted to confirm the findings. Review registration PROSPERO: CRD42017078230

BackgroundHyperprolactinaemia is a common antipsychotic (AP)-induced adverse effect, particularly in female patients.AimsThis meta-analysis examined the efficacy and safety of adjunctive aripiprazole in preventing AP-related hyperprolactinaemia in patients with first-episode schizophrenia.MethodsPubMed, PsycINFO, EMBASE, Cochrane Library, WanFang and China Journal Net databases were searched to identify eligible randomised controlled trials (RCTs). Primary outcomes were the reductions of serum prolactin level and prolactin-related symptoms. Data were independently extracted by two reviewers and analysed using RevMan (V.5.3). Weighted/standardised mean differences (WMDs/SMDs)±95% CIs were reported.ResultsIn the five RCTs (n=400), the adjunctive aripiprazole (n=197) and the control groups (n=203) with a mean of 11.2 weeks of treatment duration were compared. The aripiprazole group had a significantly lower endpoint serum prolactin level in all patients (five RCTs, n=385; WMD: −50.43 ng/mL (95% CI: −75.05 to −25.81), p2=99%), female patients (two RCTs, n=186; WMD: −22.58 ng/mL (95% CI: −25.67 to −19.49), p2=0%) and male patients (two RCTs, n=127; WMD: −68.80 ng/mL (95% CI: −100.11 to −37.49), p2=96%). The aripiprazole group was superior to the control group in improving negative symptoms as assessed by the Positive and Negative Syndrome Scale (three RCTs, n=213; SMD: −0.51 (95% CI: −0.79 to −0.24), p=0.0002; I2=0%). Adverse effects and discontinuation rates were similar between the two groups.ConclusionsAdjunctive aripiprazole appears to be associated with reduced AP-induced hyperprolactinaemia and improved prolactin-related symptoms in first-episode schizophrenia. Further studies with large sample sizes are needed to confirm these findings.

Supplemental material for Effect of adjunctive ranitidine for antipsychotic-induced weight gain: A systematic review of randomized placebo-controlled trials in Journal of International Medical Research